BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Roman HRSTKA, Petra OVESNÁ, Lucie MOUKOVÁ, Petra BRETOVÁ, Alice HLOBILKOVÁ, Michaela KOBLÍŽKOVÁ, Dita MÜNZOVÁ and Vít WEINBERGER. MISMATCH-REPAIR DEFICIENCY IS ASSOCIATED WITH A HIGHER RISK OF RECURRENCE THAN NO SPECIFIC MOLECULAR PROFILE IN EARLY-STAGE ENDOMETRIAL CANCER. In ESGO 2024. 2024. Available from: https://dx.doi.org/10.1136/ijgc-2024-ESGO.413. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{2385800, author = {Bednaříková, Markéta and Hausnerová, Jitka and Hrstka, Roman and Ovesná, Petra and Mouková, Lucie and Bretová, Petra and Hlobilková, Alice and Koblížková, Michaela and Münzová, Dita and Weinberger, Vít}, booktitle = {ESGO 2024}, doi = {http://dx.doi.org/10.1136/ijgc-2024-ESGO.413}, language = {eng}, title = {MISMATCH-REPAIR DEFICIENCY IS ASSOCIATED WITH A HIGHER RISK OF RECURRENCE THAN NO SPECIFIC MOLECULAR PROFILE IN EARLY-STAGE ENDOMETRIAL CANCER}, year = {2024} }
TY - CONF ID - 2385800 AU - Bednaříková, Markéta - Hausnerová, Jitka - Hrstka, Roman - Ovesná, Petra - Mouková, Lucie - Bretová, Petra - Hlobilková, Alice - Koblížková, Michaela - Münzová, Dita - Weinberger, Vít PY - 2024 TI - MISMATCH-REPAIR DEFICIENCY IS ASSOCIATED WITH A HIGHER RISK OF RECURRENCE THAN NO SPECIFIC MOLECULAR PROFILE IN EARLY-STAGE ENDOMETRIAL CANCER N2 - The prognostic significance of MMR deficiency (MMRd) has not been unequivocally established yet. Thus, treatment recommendations for newly diagnosed early MMRd EC patients do not differ from those with no specific molecular profile (NSMP). As a part of our research project concerning EC, this study aimed to assess the prognostic significance of MMR status and to compare clinical outcomes between MMRd and NSMP cohorts (defined as those with MMR-proficient and non-POLE ultra-mutated, TP53-wild type tumors). ER -
BEDNAŘÍKOVÁ, Markéta, Jitka HAUSNEROVÁ, Roman HRSTKA, Petra OVESNÁ, Lucie MOUKOVÁ, Petra BRETOVÁ, Alice HLOBILKOVÁ, Michaela KOBLÍŽKOVÁ, Dita MÜNZOVÁ and Vít WEINBERGER. MISMATCH-REPAIR DEFICIENCY IS ASSOCIATED WITH A HIGHER RISK OF RECURRENCE THAN NO SPECIFIC MOLECULAR PROFILE IN EARLY-STAGE ENDOMETRIAL CANCER. In \textit{ESGO 2024}. 2024. Available from: https://dx.doi.org/10.1136/ijgc-2024-ESGO.413.
|